GoodRx Holdings (GDRX) Common Equity (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Common Equity data on file, last reported at $622.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 4.95% year-over-year to $622.0 million; the trailing twelve-month figure through Mar 2026 stood at $622.0 million (down 4.95% YoY), and the FY2025 full-year result was $616.3 million, down 14.96% from the prior year.
• Common Equity rose to $622.0 million in Q1 2026, from $616.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $895.4 million in Q2 2023 to a low of $600.7 million in Q3 2025.
• A 5-year average of $731.3 million and a median of $724.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity gained 11.78% in 2023 and decreased 25.24% in 2024, its largest moves.
• Tracing GDRX's Common Equity over 5 years: stood at $814.8 million in 2022, then decreased by 6.49% to $762.0 million in 2023, then retreated by 4.9% to $724.7 million in 2024, then fell by 14.96% to $616.3 million in 2025, then grew by 0.93% to $622.0 million in 2026.
• Business Quant data shows GDRX's Common Equity at $622.0 million in Q1 2026, $616.3 million in Q4 2025, and $600.7 million in Q3 2025.